ABOS Stock Analysis: Buy, Sell, or Hold?
ABOS - Acumen Pharmaceuticals, Inc. Common Stock
$2.74
0.15 (5.79%)
▲
5d:
+23.98%
30d:
+15.61%
90d:
+7.45%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ABOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ABOS is 10.9% above its trading range ($2.47). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ABOS is 10.9% above its trading range ($2.47). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ABOS is currently trading at $2.74, which is considered fair relative to its 30-day fair value range of $2.22 to $2.47.
Technical Outlook: Technically, ABOS is in a downtrend. Immediate support is located at $2.20, while resistance sits at $2.83. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: ABOS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.40 (+170.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABOS is in a downtrend. Immediate support is located at $2.20, while resistance sits at $2.83. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: ABOS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.40 (+170.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.22 -
$2.47
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.8%)
- BULLISH: Trading 170.1% below Wall St target ($7.40)
- WARNING: Recommendation downgraded due to 10.9% overvaluation
Trading Range Analysis
30-Day Trading Range
$2.22 -
$2.47
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.20
Resistance Level
$2.83
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.82
Wall Street Target
$7.40
(+170.1%)
Share & Embed Analysis
Last updated: July 03, 2026 6:07 PM ET
Data refreshes hourly during market hours. Next update: 7:07 PM
Data refreshes hourly during market hours. Next update: 7:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Siemers
SELL
895 shares
2026-01-22
Matt Zuga
SELL
1687 shares
2026-01-22
Russell Barton
SELL
462 shares
2026-01-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
